News items related to:
-
New market intelligence report explores Senegal’s medicine & vaccines supply systems in HIV, TB, HPV & cancer areas
Senegal relies on several procurement mechanisms depending on the disease area. For HIV, medicines are procured through two channels: government...
-
New research highlights the importance of monitoring intellectual property rights in TB vaccine innovation
Frontiers in Public Health recently published research identifying potential challenges to accessing these vaccines. This important research, which increases the...
-
Colombian Civil Society Challenges Merck Patent on Monthly HIV Prevention Pill MK-8527
In its opposition filing in late 2025 with the patent office of Colombia, the Superintendency of Industry and Commerce, Fundación...
-
TNP+ Wins Landmark Patent Opposition against Unlawful HCV Treatment Patent
By successfully challenging an unlawful and potentially evergreening patent application, TNP+ has helped protect competition in the pharmaceutical market and strengthened the prospects for more affordable hepatitis C treatment in Thailand.
-
Kenya Ratifies UAE Trade Deal Threatening Access to Affordable Medicines
Kenya has ratified a trade deal that undermines access to affordable medicines, weakens local production, and is “a direct assault on the constitutional right to health” according to MMA partner KELIN, who together with civil society groups and impacted communities, sought to strike clauses in the agreement which restrict and hinder public health.
-
Civil Society Challenges the New Patent Law at the Indonesian Constitutional Court
Patent evergreening refers to various tactics employed by companies to prolong patent protection in order to maintain market monopolies and...
-
MMA Partner Celebrates Milestone in Opposing Evergreening of TB Drug Patents in Vietnam
The Intellectual Property Office of Vietnam revoked claims 1-19, 21-23, and 25-32 by J&J, stating that J&J’s argument to patent...
-
Fundación GEP Marks Landmark Wins on Lenacapavir and Cabotegravir for Affordable HIV Prevention and Treatment in Argentina
The filing of oppositions is a fundamental strategic line of the FGEP’s Health Access Program, which allows the prevention and...
-
No Borders, No Barriers: Communities Call for Universal Access to Lenacapavir
Lenacapavir – a twice-yearly HIV prevention injection – could transform the fight against HIV. But Gilead’s restrictive voluntary license excludes...
-
Activists Demand $40-a-year Generic Price for Breakthrough HIV Prevention Drug be Made Available to all Low- and Middle-Income Countries
A global coalition reacted to two deals announced today to make long acting lenacapavir (LEN-LA), a 6 monthly HIV PrEP...
-
UN High-Level Meeting on NCDs: Declaration Without Affordability Is Just Empty Words
Weaknesses in the Draft Declaration Civil society groups warn that the latest draft does not reference the right of governments...